## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of									
МОТ	TELINI e	et al.	Atty. Ref.:	620-414					
Seria	l No.	10/567,157	Group:	unknown					
Filed	: Fe	bruary 3, 2006	Examiner: Unknow						
For: THERAPEUTIC DELIVERY OF CARBON MONOXIDE									
		* * * * * * * *	* * *						
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450									
Sir:		INFORMATION DISCLOSURE	STATEMENT	:					
	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the meri							
	2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)]  N/C								
	2 .(b)	Fee Payment Pursuant to 37 CFR 1.8 [before Final Office Action or Allowance Statement or Rule 17(p) fee)]		ule 97(e) \$180.00					
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance ( Statement and Rule 17(p) fee), but before							

MOTTELINI et al. Serial No. 10/567,157

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

	4.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.								
This p	This paper is submitted in accordance with:									
$\boxtimes$	5.	37 (	CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]							
	6.	37 ( and	7 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; nd							
		a)	The required Statement made in item 8 below; or							
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.							
	7.		CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) tement <u>and</u> Rule 17(p) fee), but before final fee payment]; and							
		a)	The fee (\$180.00) required by 37 CFR $\S1.17(p)$ is submitted herewith; and							
		b)	The required Statement is stated in item 8 below.							
	8.	Stat	tement under 37 CFR 1.97(e)							
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or							
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.							

MOTTELINI et al. Serial No. 10/567,157

 Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

> Respectfully submitted, NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36.663

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

'Examiner

/Amy Lewis/

Sheet	1	of 4							
NFORM	IATI	ON DISCLOSURE	ATTY, DOCKET NO.	SERIAL NO.					
	CI	ITATION	620-414 APPLICANT	10/567,157					
(Uso r	ovor	al sheets if necessary)	MOTTELINI et al.	GROUP					
(050)	SCVCIA	ii sileets ii liecessaiy)	February 3, 2006	unknown					
	0.	THER DOCUMENT	S (including Author.	Title, Date, Pertinent pages, etc.)					
		Tenhunen R, Marver HS Chem. 1969;244:6388-6		eme oxygenase. Characterization of the enzyme. J Biol					
		Toxicol. 1997;37:517-55	4.	lator of second messenger gases. Annu Rev Pharmacol					
	- (	Science, 1993;259:381-	384.	er SH. Carbon monoxide: a putative neural messenger.					
	.			C, Levere RD, Schwartzman ML. Treatment with tin taneously hypertensive rats. Science. 1989;243:388-					
		Marks GS, Brien JF, Nai Trends Pharmacol Sci. 1		Ooes carbon monoxide have a physiological function?					
		Ackerley C. Carbon mor of muscle tone. Br J Pha	noxide formation in the du armacol. 1997;120:599-60						
	·	carbon monoxide in cen	tral regulation of arterial p	a M, Talman WT, Nasjletti A. Role of endogenous ressure. Hypertension. 1997;30:962-967.					
		Wang R, Wang ZZ, Wu J Pharmacol. 1997;121:		uced vasorelaxation and the underlying mechanisms. Br					
	Ĭ			en CJ, Winslow RM. Heme oxygenase-1-derived carbon hypertensive responses in vivo. Circ Res. 1998;83:568-					
	10 Sammut IA, Foresti R, Clark JE, Exon DJ, Vesely MJJ, Sarathchandra P, Green CJ, Motterlini R. monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels haeme oxygenase-1. Br J Pharmacol. 1998;125:1437-1444.								
		endogenous modulator	of sinusoidal tone in the p	va T, Shinoda Y, Ishimura Y. Carbon monoxide: an erfused rat liver. J Clin Invest. 1995;96:2431-2437.					
				nas S. Carbon monoxide controls the proliferation of n. 1997;272:32804-32809.					
	13 Sato K, Balla J, Otterbein L, Smith RN, Brouard S, Lin Y, Csizmadia E, Sevigny J, Robson G, Choi AM, Bach FH, Soares MP. Carbon monoxide generated by heme oxygenase-1 su rejection of mouse-to-rat cardiac transplants. J Immunol. 2001;166:4185-4194.								
		Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000:6:422-8							
		generated by heme oxyg	genase 1 suppresses end	Bach FH, Choi AM, Soares MP. Carbon monoxide othelial cell apoptosis. J Exp Med. 2000;192:1015-1026.					
				E, Choi AM. Carbon monoxide inhibits human airway ated protein kinase pathway. Am J Respir Cell Mol Biol.					
		Otterbein LE, Mantell LL Am J Physiol. 1999;276:		oxide provides protection against hyperoxic lung injury.					
1 1	- 1								

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

09/28/2010

Date Considered

NEOF	184 A T	ION DISCLOS	UDE ATTY. D	OCKET NO.		SE	RIAL NO.					
NFOR		ITATION		= 620-414			10/567,157					
	`	IIAIION	APPLICA			- 10	7507,10	1				
			MOTT	MOTTELINI et al.								
(U	se seve	ral sheets if necessary)	FILING D	DATE		GR	OUP					
			Febru	ary 3, 2006		ur	known					
			FORE	IGN PATE	NT DOCUMEN	NTS						
		DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	TRANS	NO.		
	lock						L	SUBULASS	150	110		
		NO 02/092075	11/2002		WIPO		-					
		EP 0 034 238	08/1981		Europe							
		WO 93/05795	04/1993		WIPO							
		EP 0 181 721	05/1986		Europe							
		NO 03/066067	08/2003		WIPO							
		P 0 632 026 A	01/1995		Europe							
		VO 94/01413 A	01/1994		WIPO							
	50 V	VO 01/25243 A	04/2001	001 WIPO								
		OTHER DOCU	MENTS (inc	luding Aut	hor, Title, Dat	e, Pe	rtinent	pages, et	c.)			
	18	Fujita T, Toda K, I										
		injury by inhaled o										
	19	Foresti R, Motterli				nteract	ion with n	itric oxide ir	the co	ntrol of		
-	100	cellular homeosta Otterbein LE. Carl				ranadi	on of on	an ald ann	malagu	lo.		
	20	Antioxid Redox Si			ili-ililialililialory p	roperu	es or an a	ige-old gas	molecu	ie.		
	21	Chauveau C, Bou			. P. Braudeau C.	Renau	ıdin K. Te	sson L. Sou	ılillou JF	P. Iver S.		
	-'	Buelow R, Anegor										
		rejection. Am J Tr	ansplant. 2002	;2:581-592.	,,							
	22	Motterlini R, Fores								cules:		
		potential applications for the treatment of cardiovascular dysfunction. In: Carbon Monoxide and Cardiovascular Functions. Wang R, ed. 2002. CRC Press, Boca Raton, Florida.										
-	-	Cardiovascular Fu	inctions, wang	R, ed. 2002.	CRC Press, Boc	a Kato	n, Florida					
	23	Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res. 2002;90:E17-E24.							ng			
	24									protectiv		
	47	Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, Foresti R, Motterlini R. Cardioprote actions by a water-soluble carbon monoxide-releasing molecule. Circ Res. 2003;93:e2-e8.								p 1 1 - 1		
	26	Johnson TR, Man	n BE, Clark JE	, Foresti R, G	reen CJ, Motterlii	ni R. M	letal carb	onyls: a nev	v class o	of		
		pharmaceuticals?										
	27	Motterlini R, Mann BE, Johnson TR, Clark JE, Foresti R, Green CJ. Bioactivity and pharmacological action							al actions			
<u> </u>	-	of carbon monoxide-releasing molecules. Curr Pharm Des. 2003;In press										
	28	Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, Egli A, Abram U, Mach JP, Pluckthun										
		A, Schubiger PA. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a no Tc(I)-carbonyl complex. Nat Biotechnol. 1999;17:897-901.							iii a iiove			
	29					. Waib	el R. Tou	rwe D. Jear	nnin L. I	terbeke k		
	29 Egli A, Alberto R, Tannahill L, Schibli R, Abram U, Schaffland A, Waibel R, Tourwe D, Jeannin L, Iterb Schubiger PA. Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activities.											
	Nucl Med. 1999;40:1913-1917.							•				
aminer		/Amy Lev	vie/		Date Considere	d		09/28/2010	1			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

NFORMATION DISCLOSURE			RE ATTY. DOCK	ET NO.	SERIA	. NO.				
	С	ITATION	620-414							
			APPLICANT							
			MOTTEL FILING DATE	.INI et al.	GROU	•				
(USI	e sever	ral sheets if necessary)								
			February		unkn	own				
XAMINER			U.S. I	PATENT DOCUMENTS	<u> </u>			FILING DATE		
INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	IF APPROPRIAT		
	44	4,312,989	01/1982	Spielvogel et al.						
	45	5,254,706	10/1993	Spielvogel et al.						
	-		<del>  </del>				ļ. —			
	$\vdash$									
	-									
	+						-			
	_	OTHER DOCUM	ENTS (includ	ling Author, Title, Da	te. Perti	nent pa	ages. etc.	)		
		Alberto R, Schibli R	, Egli A, Schubig	ger AP, Abram U, Kaden TA	A. A novel	organon	netallic aqua	complex of		
				ng of biomolecules: Synthesis of [Tc-99m(OH2)(3)(CO)(3)](+) from [(TcO4)-Tc-						
		99m](-) in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;12 7988.						;120:7987-		
	31		, Wheatley N, So	chibli R, Schubiger AP. Syn	thesis and	properti	ies of boran	ocarbonate: a		
				ource for the aqueous preparation of [(99m)Tc(OH(2))3(CO)3]+. J Am Chem Soc.						
-	32	2001;123:3135-313 Abraham NG Drum		n JD, Kappas A. The biolog	nical eignif	icance a	nd physiolo	gical role of		
	32			hem 1996;6:129-68.	Jicai sigiiii	icarice a	na priyololo	gical fole of		
	33			nadia E, Takigami K, Sato						
	34			1 can determine cardiac xe IH, Turka LA. Antibody-indu						
	34			ind anti-apoptotic genes. N				is is prevented		
	35	Clark JE, Foresti R,	Sarathchandra	athchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin iic myocardial dysfunction. Am J Physiol Heart Circ Physiol 2000;278:H643-51. derick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of Nature Med 1996;2:87-90.						
	<u> </u>									
	36									
	37			zog C, Wanner GA, Hanse	lmann R,	Zhang J	X, Clemens	MG, Larsen R		
				en stress-response and va-	ess-response and vascular control in hepatic portal circulation. Ar					
	20	J Physiol 1996;271:		able I. I. Industion of home	2000000	1 (40	1) ofter trou	matic brain		
	اموا	injury in the rat. Ne			nduction of heme oxygenase-1 (HO-1) after traumatic brain 30.					
	39	Yet SF, Pellacani A	, Patterson C, T	an L, Folta SC, Foster L, Le						
				ascular smooth muscle cells	s. A link to	endotox	ic shock. J	Biol Chem		
-	40	1997;272:4295-301 Otterbein I.E. Kolls		Cook JL, Alam J, Choi AMK	Exogeno	nus admi	nistration of	heme		
	70	oxygenase-1 by ge		des protection against hype						
	1	1999;103:1047-54.								
	46	Iris H. Hall et al. "Th 12, 1995.	ne anti-inflamma	tory activity of boron deriva	tives in ro	dents*. N	1etal Based	Drugs, 2(1), 1		
$\vdash$	_	12, 1995.								
	1									
			ris/							

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Form PTO-FB-A820 (Also PTO-1449)

Shee	t 4	Ιo	f 4
------	-----	----	-----

Sileet	4	01 4								
INFORI	MAT	ION DISCLOSUR	E ATTY. E	ATTY, DOCKET NO.			SERIAL NO.			
	С	ITATION		620-414		10.	10/567,157			
			APPLIC							
01		-1-6	MOT	TELINI et al	-	007	GROUP			
(USE	sever	al sheets if necessary)								
				uary 3, 2006			known			
*EXAMINER			U.	U.S. PATENT DOCUMENTS					FILING DATE	
INITIAL	_	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	IF APPROPRIATE	
	_									
	-						-			
		-	-				+	-	-	
							+			
		OTHER DOCUME	NTS (inc	cluding Aut	hor, Title, Da	te, Per	tinent pa	ges, etc.	)	
		Miller M C et al. "The phenylalanine methyl		logical activitie	s of the metabol	ites of N	l-'(trimethyl	amineboryl)	-carbonyl!-L-	
		METAL-BASED DRU		ISRAFL vol 3	no 5 1996 par	nes 219	-226			
		XP009038194		,	, 0,, p	g	,			
		ISSN: 0793-0291								
		Page 220; figure 1	4							
	52	Page 222; paragraph STONE JAMES R ET	AI: "Syne	emistic activati	on of soluble qua	anylate cyclise by YC-1 and carbon monoxide:				
	52	Implications for the ro	le of cleav	of cleavage of the iron-histidine bond during activation by nitric oxide"						
		CHEMISTRY AND BI				•	•			
		Vol. 5, no. 5, May 199	98 (1998-0	(1998-05),						
		pages 255-261 XP002300901, ISSN:	4074 550							
		the whole document	10/4-552	11						
	53	Durante "Heme Oxyg	enase-1 ir	Growth Contr	ol and its clinical	applica	tion to vasc	ular diseas	e" Journal of	
	"	Cell physiology, June								
<u> </u>	195:373-382									
-										
-	_									
	_									
-	-									
-	_									
-	-									
-	$\vdash$									
Examiner	_	/Amy I	wie/		Date Considere	ed	09	/28/2010		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)